Abstract:To retrospectively investigate the feasibility of radiofrequency ablation (RFA) in treating advanced hepatocellular carcinoma (HCC) using standard ultrasound-guided percutaneous RFA.A total of 655 patients with unresectable advanced HCC underwent ultrasound-guided percutaneous RFA therapy at our institution between July 2000 to September 2001. Ninety-two of those patients, representing 136 tumors, were selected for analysis based on the following criteria: presence of UICC/AJCC-TNM (6th edition) stage III and IV advanced HCC, (III: n=82 patients, with 126 tumors; IV: n=10 patients, with 10 tumors); extensive portal vein or inferior vena cava tumor thrombus; extrahepatic metastasis after surgical resection; and complete follow-up data. Follow-up consisted of enhanced computed tomography (CT) performed at one month post-RFA treatment, then every three months. Contrast-enhanced ultrasound (CEUS) was performed in 51 (55.4%) patients before RFA. The standard treatment using optimal strategies were applied in (72.8%) 67 patients. The established strategies included: (1) select RFA indications based on CEUS results; (2) design radical protocols based on invasive range showed by CEUS; (3) multiple overlapping ablations based on mathematical protocols; (4) two or three bipolar RFA electrodes with three-dimensional localization; (5) color ultrasound-guided percutaneous ablation of tumor feeding artery (PAA)/transcatheter arterial chemoembolization (TACE) + RFA for HCC with rich supply. The other 25 patients (27.2 %) were treated with conventional RFA protocols. The ablation procedure was considered a success if no abnormal enhancement or wash-out was detected in the treated area on the CT scan at one month. All patients had received liver protection treatments following RFA. Chi-squared test or Fisher's exact test were used to compare the early complete tumor necrosis rates and the local recurrence rates. Survival was estimated by Kaplan-Meier analysis and log-rank test. P less than 0.05 was considered statistically significant.The RFA-treated tumors ranged in size from 1.5 to 7.0 cm (average: 4.5 cm). Fifty-nine patients had solitary tumor, and the remaining 33 had multiple tumors (2 to 4 tumors). Patients were classified by Child-Pugh score as A (n=58), B (n=32) and C (n=2). Early complete tumor necrosis rate after initial RFA was 90.4% (123/136 tumors). Serious complications developed in two patients (2.2%). No treatment-related death occurred. Follow-up ranged from 3-134 months. Local recurrence rate was 16.9% (23/136 tumors). The 1-, 3- and 5-year overall survival rates were 83.3%, 48.3% and 21.9%, respectively, and the median survival time was 35 months. Stratification analysis indicated the early complete tumor necrosis rate was higher in groups of patients with Child-Pugh A score (98.3%) , CEUS administration (98.0%), and standard treatment (97.0%). The local recurrence rate was lower in groups of patients with tumors less than or equal to 3.0 cm (5.9%), CEUS administration (11.8%), and standard treatment (16.4%). The 5-year survival was significantly higher in patients with Child-Pugh A, tumors less than or equal to 3.0 cm, CEUS administration, and standard treatment (all, P less than 0.05).RFA treatment of patients with advanced HCC, tumors less than 7.0 cm, and without thrombosis in the main vessels was efficacious. The RFA treatment strategy and subsequent liver protection therapy in RFA may improve survival.

Thermal ablation of hepatocellular carcinoma in patients with abnormal coagulation function

Thrombotic Thrombocytopenic Purpura after Radiofrequency Ablation of Hepatocellular Carcinoma: A Case Report.

[Percutaneous Microwave/Radiofrequency Ablation Liver Partition and Portal Vein Embolization for Planned Hepatectomy for Colorectal Liver Metastases with Insufficient Future Liver Remnant].

Safety of local thermal ablation in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia

Thermal Ablation of Hepatic Hemangioma: A Multi-Center Experience with Long-Term Outcomes

Percutaneous Thermal Ablation Combined with Simultaneous Transarterial Chemoembolization for Hepatocellular Carcinoma ≤5 Cm

[Efficacy of Radiofrequency Ablation of 343 Patients with Hepatic Tumor and the Relevant Complications].

Risk factors of complications after thermal ablation for hepatocellular carcinoma: the role of assessment of liver background

P0071 Diagnosis and treatment of coagulopathy following percutaneous cryoablation of liver tumours: Experience in 372 patients

Radiofrequency Ablation of Recurrent Hepatocellular Carcinoma after Hepatectomy: Therapeutic Efficacy on Early- and Late-Phase Recurrence

Treatment Efficacy of Radiofrequency Ablation of 338 Patients with Hepatic Malignant Tumor and the Relevant Complications.

Value of artificial ascites to assist thermal ablation of liver cancer adjacent to the gastrointestinal tract in patients with previous abdominal surgery

Laparoscopic Ultrasound Graded Radiofrequency Ablation for Hepatocellular Carcinoma:Preliminary Experience

Long-term efficacy of radiofrequency ablation in 446 patients with hepatocellular carcinoma]

Correlation of Needle Biopsy-Acquired Histopathologic Grade of Hepatocellular Carcinoma with Outcomes after Thermal Ablation

Efficacy of radiofrequency ablation to treat advanced hepatocellular carcinoma]

Tips for Preparing and Practicing Thermal Ablation Therapy of Hepatocellular Carcinoma

Image-Guided Thermal Ablation for Hepatic Epithelioid Hemangioendothelioma: A Multicenter Experience

Preliminary study on percutaneous ultrasound-guided radiofrequency ablation for hepatocellular carcinoma with artificial pleural effusion

Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: a multi-center study in China.

[Ultrasound-guided percutaneous thermal ablation assisted by artificial ascites and soft tissue edema in the treatment of special-region hepatic tumors]